| 前收市價 | 1,033.14 |
| 開市 | 0.00 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 0.00 - 0.00 |
| 52 週波幅 | |
| 成交量 | |
| 平均成交量 | 1,962 |
| 市值 | 115.159B |
| Beta 值 (5 年，每月) | 0.13 |
| 市盈率 (最近 12 個月) | 0.15 |
| 每股盈利 (最近 12 個月) | 70.31 |
| 業績公佈日 | 2024年8月01日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
Investor's Business DailySwing Trading Regeneron Stock Shows How To Bob And Weave
What do boxers and swing traders have in common? Avoiding big hits and striking at opportunities when they come. Here's how.
BenzingaEurope Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. Specifically, the approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) or on a combination of LABA and LAMA if ICS is not appropriate. Sanofi SA (NASDAQ
ZacksRegeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
